Clinical Trials Logo

Clinical Trial Summary

Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05065970
Study type Interventional
Source MorphoSys AG
Contact Morphosys Clinical Program Lead
Phone 8446671992
Email [email protected]
Status Recruiting
Phase Phase 2
Start date August 31, 2021
Completion date January 2024